SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034
Johnson & Johnson Services, Inc.(Janssen Pharmaceuticals, Inc.)
Lexicon Pharmaceuticals, Inc.
Merck & Co., Inc.
Sanofi
TheracosBio, LLC
ksm
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
The global SGLT2 inhibitors market size is expected to reach USD 32.75 billion by 2034, according to a new study by Polaris Market Research. The report "SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report, By Indication (Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region; Segment Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The sodium-glucose cotransporter 2 (SGLT2) inhibitors market has emerged as a significant segment of the global pharmaceutical industry, driven by the increasing prevalence of type 2 diabetes (T2D), heart failure, and chronic kidney diseases (CKD). SGLT2 inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2, a protein responsible for reabsorbing glucose from the kidneys into the bloodstream
The market for SGLT2 inhibitors is experiencing significant growth due to their increasing efficacy in treating type 2 diabetes (T2D) by inhibiting glucose reabsorption in the kidneys and thereby lowering blood sugar levels. This expansion is attributed to the increasing rising obesity rates, sedentary lifestyles, aging populations, and unhealthy diets. Genetic predisposition, urbanization, and economic differences also contribute to the surge in diabetes cases in North America and globally. Thereby boosting demand for SGLT2 inhibitors.
The COVID-19 pandemic has further accelerated the adoption of SGLT2 inhibitors as diabetic patients sought effective treatments to manage their condition and mitigate the risk of severe COVID-19 complications. Additionally, the pandemic has led to a surge in the use of online pharmacies, facilitating accessibility to these medications. Furthermore, favorable reimbursement policies, regulatory approvals, and ongoing innovations in drug formulations further bolster the market.
SGLT2 Inhibitors Market Report Highlights
In 2024, the type 2 diabetes segment accounted for the largest revenue share in the SGLT2 inhibitors market. Urbanization often leads to lifestyle changes characterized by decreased physical activity, increased consumption of processed foods, and higher stress levels. These factors contribute to the rising prevalence of obesity and type 2 diabetes, significantly driving the SGLT2 inhibitors market.
The online pharmacies segment is growing at the highest CAGR during the forecast period. Online pharmacies often offer competitive pricing and discounts on medications as a result of reduced overhead costs associated with online operations.
In 2024, North America SGLT2 inhibitors market accounted for the largest market due to the increasing chronic stress and poor mental. Additionally, the increasing prevalence of diabetes patients in North America has led to a higher demand for SGLT2 inhibitors in the region.
Asia Pacific accounted for the fastest growth in the market. Governments in the region are increasingly investing in healthcare infrastructure and initiatives to enhance access and quality. These efforts support pharmaceutical markets and the adoption of medications like SGLT2 inhibitors.
The global key market players include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.
Polaris Market Research has segmented the SGLT2 inhibitors market report based on indication, drug, distribution channel, and region:
By Indication Outlook (Revenue - USD Billion, 2020 - 2034)
Cardiovascular
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Others
By Drug Outlook (Revenue - USD Billion, 2020 - 2034)
Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Regional Outlook (Revenue - USD Billion, 2020 - 2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global SGLT2 Inhibitors Market Insights
4.1. SGLT2 Inhibitors Market - Distribution Channel Snapshot
4.2. SGLT2 Inhibitors Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. The Global Rise of the Aging Population is Driving Market Growth
4.2.1.2. Rising New Drug Approvals Drive Market Outlook
4.2.2. Restraints and Challenges
4.2.2.1. High Cost of Medication
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. SGLT2 Inhibitors Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global SGLT2 Inhibitors Market, by Indication
5.1. Key Findings
5.2. Introduction
5.2.1. Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
5.3. Cardiovascular
5.3.1. Global SGLT2 Inhibitors Market, by Cardiovascular, by Region, 2020-2034 (USD Billion)
5.4. Chronic Kidney Disease (CKD)
5.4.1. Global SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Region, 2020-2034 (USD Billion)
5.5. Type 2 Diabetes
5.5.1. Global SGLT2 Inhibitors Market, by Type 2 Diabetes, by Region, 2020-2034 (USD Billion)
5.6. Others
5.6.1. Global SGLT2 Inhibitors Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global SGLT2 Inhibitors Market, by Drug
6.1. Key Findings
6.2. Introduction
6.2.1. Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
6.3. Farxiga (Dapagliflozin)
6.3.1. Global SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Region, 2020-2034 (USD Billion)
6.4. Inpefa (Sotagliflozin)
6.4.1. Global SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Region, 2020-2034 (USD Billion)
6.5.Invokana (Canagliflozin)
6.5.1. Global SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Region, 2020-2034 (USD Billion)
6.6. Jardiance (Empagliflozin)
6.6.1. Global SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Region, 2020-2034 (USD Billion)
6.5. Qtern (Dapagliflozin/Saxagliptin)
6.5.1. Global SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Region, 2020-2034 (USD Billion)
6.5. Other SGLT2 Inhibitors
6.5.1. Global SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Region, 2020-2034 (USD Billion)
7. Global SGLT2 Inhibitors Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
7.3.1. Global SGLT2 Inhibitors Market, by Hospital Pharmacies, By Region, 2020-2034 (USD Billion)
7.4. Online Pharmacies
7.4.1. Global SGLT2 Inhibitors Market, by Online Pharmacies, By Region, 2020-2034 (USD Billion)
7.5. Retail Pharmacies
7.5.1. Global SGLT2 Inhibitors Market, by Retail Pharmacies, By Region, 2020-2034 (USD Billion)
8. Global SGLT2 Inhibitors Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. SGLT2 Inhibitors Market - North America
8.3.1. North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.3.2. North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.3.3. North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.3.4. SGLT2 Inhibitors Market - U.S.
8.3.4.1. U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.3.4.2. U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.3.4.3. U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.3.5. SGLT2 Inhibitors Market - Canada
8.3.5.1. Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.3.5.2. Canada.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.3.5.3. Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4. SGLT2 Inhibitors Market - Europe
8.4.1. Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.2. Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.3. Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.4. SGLT2 Inhibitors Market - UK
8.4.4.1. UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.4.2. UK.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.4.3. UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.5. SGLT2 Inhibitors Market - France
8.4.5.1. France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.5.2. France.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.5.3. France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.6. SGLT2 Inhibitors Market - Germany
8.4.6.1. Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.6.2. Germany.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.6.3. Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.7. SGLT2 Inhibitors Market - Italy
8.4.7.1. Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.7.2. Italy.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.7.3. Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.8. SGLT2 Inhibitors Market - Spain
8.4.8.1. Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.8.2. Spain.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.8.3. Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.9. SGLT2 Inhibitors Market - Netherlands
8.4.9.1. Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.9.2. Netherlands.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.9.3. Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.10. SGLT2 Inhibitors Market - Russia
8.4.10.1. Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.10.2. Russia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.10.3. Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4.11. SGLT2 Inhibitors Market - Rest of Europe
8.4.11.1. Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.4.11.2. Rest of Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4.11.3. Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5. SGLT2 Inhibitors Market - Asia Pacific
8.5.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.2. Asia Pacific.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.3. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.4. SGLT2 Inhibitors Market - China
8.5.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.4.2. China.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.4.3. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.5. SGLT2 Inhibitors Market - India
8.5.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.5.2. India.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.5.3. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.6. SGLT2 Inhibitors Market - Malaysia
8.5.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.6.2. Malaysia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.6.3. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.7. SGLT2 Inhibitors Market - Japan
8.5.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.7.2. Japan.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.7.3. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.8. SGLT2 Inhibitors Market - Indonesia
8.5.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.8.2. Indonesia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.8.3. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.9. SGLT2 Inhibitors Market - South Korea
8.5.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.9.2. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.9.3. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.10. SGLT2 Inhibitors Market - Australia
8.5.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.10.2. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.10.3. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5.11. SGLT2 Inhibitors Market - Rest of Asia Pacific
8.5.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.5.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6. SGLT2 Inhibitors Market - Middle East & Africa
8.6.1. Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.2. Middle East & Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.3. Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6.4. SGLT2 Inhibitors Market - Saudi Arabia
8.6.4.1. Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.4.2. Saudi Arabia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.4.3. Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6.5. SGLT2 Inhibitors Market - UAE
8.6.5.1. UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.5.2. UAE.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.5.3. UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6.6. SGLT2 Inhibitors Market - Israel
8.6.6.1. Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.6.2. Israel.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.6.3. Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6.7. SGLT2 Inhibitors Market - South Africa
8.6.7.1. South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.7.2. South Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.7.3. South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6.8. SGLT2 Inhibitors Market - Rest of Middle East & Africa
8.6.8.1. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.6.8.2. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6.8.3. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7. SGLT2 Inhibitors Market - Latin America
8.7.1. Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.7.2. Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7.3. Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7.4. SGLT2 Inhibitors Market - Mexico
8.7.4.1. Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.7.4.2. Mexico.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7.4.3. Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7.5. SGLT2 Inhibitors Market - Brazil
8.7.5.1. Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.7.5.2. Brazil.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7.5.3. Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7.6. SGLT2 Inhibitors Market - Argentina
8.7.6.1. Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.7.6.2. Argentina.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7.6.3. Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7.7. SGLT2 Inhibitors Market - Rest of Latin America
8.7.7.1. Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
8.7.7.2. Rest of Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7.7.3. Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)